KLOW Stack — Research Reference
The KLOW stack is the most comprehensive healing combination in this reference — an extension of the GLOW stack (BPC-157 + TB-500 + GHK-Cu) with the addition of KPV (Lys-Pro-Val), a naturally occurring α-MSH-derived tripeptide with pronounced anti-inflammatory and gut-healing properties. The stack is used in anecdotal research contexts for comprehensive tissue regeneration, systemic anti-inflammation, gut health support, and skin/hair benefits.
Stack Overview
| Parameter | Detail |
|---|---|
| Components | BPC-157 + TB-500 + GHK-Cu + KPV |
| Mechanisms | Cytoprotection (BPC-157) + angiogenesis/regeneration (TB-500) + collagen/skin (GHK-Cu) + anti-inflammation/gut (KPV) |
| Primary reported goal | Comprehensive healing, gut health, anti-inflammation, skin/hair regeneration |
| Category | Healing & Recovery |
Research context: All four components have independent research bases. The combination is based on complementary mechanisms and anecdotal research accounts. No published clinical trial specifically studies all four compounds together.
Components
| Component | Class | Primary Mechanism | Standard Research Form |
|---|---|---|---|
| BPC-157 | Gastric pentadecapeptide | Cytoprotection, tissue repair, NO pathway | 200–500 mcg/day SubQ/IM |
| TB-500 (Thymosin Beta-4) | Thymic peptide | G-actin sequestration, angiogenesis, anti-inflammation | 2–5 mg/week SubQ/IM |
| GHK-Cu | Copper tripeptide | Collagen/elastin synthesis, wound healing, hair, antioxidant | 1–2 mg/day SubQ or topical |
| KPV | α-MSH tripeptide | NFκB inhibition, gut anti-inflammation, cytokine modulation | 200–500 mcg/day SubQ or oral |
For individual compound profiles, see:
- BPC-157 Research Reference →
- TB-500 Research Reference →
- GHK-Cu Research Reference →
- KPV Research Reference →
Commonly Reported Protocol
The following information represents commonly reported research ranges from anecdotal accounts. These are not medical recommendations.
Loading Phase (Weeks 1–4)
| Component | Loading Dose | Frequency |
|---|---|---|
| BPC-157 | 250–500 mcg per day | Daily (SubQ or IM) |
| TB-500 | 4–10 mg per week | Once or split twice weekly |
| GHK-Cu | 1–2 mg per day | Daily (SubQ/IM or topical) |
| KPV | 200–500 mcg per day | Daily (SubQ or oral) |
Maintenance Phase (Weeks 5–16)
| Component | Maintenance Dose | Frequency |
|---|---|---|
| BPC-157 | 200–500 mcg per day | Daily or 5 days/week |
| TB-500 | 2–5 mg per week | Once or split twice weekly |
| GHK-Cu | 1–2 mg per day | Daily or 5 days/week |
| KPV | 200–500 mcg per day | Daily (SubQ) or 500 mcg–1 mg orally |
KPV Route Selection
KPV’s notable characteristic is its reported oral activity — a property most peptides lack. In the KLOW stack context:
- Subcutaneous KPV is described for systemic anti-inflammatory effects
- Oral KPV is described specifically for gut-focused research — intestinal inflammation, gut permeability, and IBD-related conditions. Oral doses in research accounts are typically higher (500 mcg–1 mg/day) to account for lower bioavailability than subcutaneous
- Some research accounts describe using both routes simultaneously
Simplified Administration
For researchers managing four compounds simultaneously, anecdotal accounts describe several approaches to reduce injection burden:
- BPC-157 and KPV can be injected at the same site in the same syringe (both SubQ, small total volume)
- TB-500 is typically injected separately (larger volume)
- GHK-Cu SubQ can be co-administered with BPC-157 if oral KPV is used
- GHK-Cu topical does not require injection
Reported Synergies
BPC-157 + KPV (gut health): Both compounds have published research bases in the gut health and intestinal inflammation space. BPC-157’s cytoprotective effects on the GI mucosa and KPV’s anti-inflammatory effects on intestinal epithelial cells are proposed to produce complementary gut-healing effects. This combination is the most frequently described reasoning for adding KPV to the Wolverine/GLOW foundation.
TB-500 + KPV (systemic anti-inflammation): TB-500’s systemic anti-inflammatory properties and KPV’s NFκB-mediated cytokine suppression are proposed to reduce systemic inflammatory burden from complementary angles — one via actin modulation and T cell regulation, the other via cytokine pathway suppression.
GHK-Cu + KPV (skin and wound healing): Both compounds have wound healing and anti- inflammatory properties at the tissue level. Research on the C-terminal fragments of α-MSH (including KPV) and GHK-Cu have both reported effects on skin inflammation and repair. Anecdotal accounts describe this combination as particularly effective for inflammatory skin conditions.
BPC-157 + TB-500 + GHK-Cu foundation: See the GLOW Stack → for a detailed discussion of the three-component synergies. KLOW builds on this base.
Reported Effects
The following effects have been reported in anecdotal research accounts. This list reflects the research landscape, not confirmed clinical outcomes.
Comprehensive Healing
KLOW encompasses all the reported healing effects of the Wolverine and GLOW stacks, with KPV adding particular anti-inflammatory depth. Anecdotal accounts of the full KLOW combination describe the most pronounced and broad-spectrum healing effects of any stack in this reference.
Gut Health and Intestinal Inflammation
The most distinctive addition of KPV relative to GLOW is gut health. Anecdotal research accounts for KLOW with oral or subcutaneous KPV describe improvements in IBS symptoms, IBD-associated discomfort, gut permeability-related symptoms, and general gastrointestinal comfort. Cell and animal research on KPV specifically supports intestinal anti-inflammatory effects. BPC-157 adds cytoprotective gut coverage.
Systemic Anti-inflammatory Effects
Multiple anti-inflammatory mechanisms — TB-500’s anti-inflammatory properties, KPV’s NFκB and cytokine suppression, and GHK-Cu’s antioxidant and anti-inflammatory gene activation — converge in KLOW. Anecdotal accounts describe marked reduction in systemic inflammatory markers (joint swelling, post-exercise soreness, general inflammatory burden) with the full combination.
Skin, Hair, and Collagen
GHK-Cu contributes collagen synthesis and skin/hair effects as described in the GLOW stack. KPV may provide additional anti-inflammatory support relevant to inflammatory skin conditions (though this specific combination has not been studied clinically).
Recovery from Complex Injuries
Anecdotal accounts of KLOW are often from researchers managing more complex or multi-site conditions — combining musculoskeletal injury recovery with gut issues, inflammatory conditions, or skin concerns — where the breadth of the stack’s proposed coverage is considered advantageous.
Reported Side Effects
Reported side effects in research and anecdotal accounts include the following.
| Side Effect | Frequency Reported |
|---|---|
| Injection site redness or mild pain | Common (multiple daily injections) |
| Injection site fatigue (multiple daily injections) | Occasionally reported |
| Loose stools (oral KPV; higher doses) | Occasionally reported |
| Skin copper tint at GHK-Cu injection site | Occasionally reported; transient |
| Fatigue (initial days) | Rarely reported |
The KLOW stack has a minimal reported side effect profile. The primary practical challenge is managing four compounds — injections, storage, and reconstitution. Oral KPV reduces injection burden for the gut-targeted component.
WADA status: TB-500 is prohibited by WADA and all major anti-doping bodies. Athletes subject to anti-doping rules should review current WADA prohibitions.
Research Context
KLOW is an anecdotal combination without published clinical trial data as a multi-compound stack. Each component has independent published research. BPC-157 and KPV share the strongest mechanistic rationale for gut health applications; TB-500 and GHK-Cu the strongest for systemic and connective tissue healing.
The KLOW stack represents a meaningful investment in research compound administration — four compounds with overlapping but distinct mechanisms. Anecdotal accounts most commonly describe it in the context of persistent or complex conditions where simpler approaches have been considered insufficient.
Frequently Asked Questions
Is the full KLOW stack necessary, or is a simpler combination better? Anecdotal research accounts suggest starting with the simplest relevant combination:
- For musculoskeletal healing: Wolverine (BPC-157 + TB-500)
- For the above + skin/hair/collagen: GLOW (+ GHK-Cu)
- For the above + gut inflammation/systemic anti-inflammation: KLOW (+ KPV) The added complexity of KLOW is most often described as warranted for individuals with specific gut health concerns alongside musculoskeletal recovery goals.
Can KPV be used orally while the other compounds are injected? Yes. Oral KPV is specifically described in this context in anecdotal research accounts, reducing the injection count to three compounds (BPC-157, TB-500, GHK-Cu — or two injections if BPC-157 and GHK-Cu are combined). Oral KPV is generally targeted at gut health applications; subcutaneous KPV is described for systemic anti-inflammatory applications.
How does KLOW compare to BPC-157 alone for gut health? BPC-157 has a well-characterised research profile for GI healing and cytoprotection. KPV adds a distinct anti-inflammatory mechanism (NFκB suppression, cytokine modulation) that BPC-157 does not directly replicate. Anecdotal accounts in gut-health-focused research contexts describe the two as complementary: BPC-157 for mucosal repair and cytoprotection, KPV for reduction of inflammatory signalling driving ongoing tissue damage.
How long should a KLOW cycle run? Anecdotal research accounts most commonly describe 12–24 weeks. Longer cycles are justified by the slow nature of collagen remodelling (GHK-Cu) and the need for sustained anti- inflammatory effects. Some accounts describe indefinite low-dose maintenance (particularly for KPV in chronic gut conditions). TB-500 cycling is often tied to athlete off-competition periods given WADA prohibition.
Related Stacks
- Wolverine — BPC-157 + TB-500 — Core healing foundation
- GLOW — BPC-157 + TB-500 + GHK-Cu — KLOW without KPV
- CJC-1295 + Ipamorelin — Growth hormone optimisation stack